{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T16:42:02Z","timestamp":1723135322537},"reference-count":34,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,11]]},"DOI":"10.7759\/cureus.24047","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T19:26:43Z","timestamp":1649705203000},"source":"Crossref","is-referenced-by-count":0,"title":["Safety and Long-Term Survival Outcome in Patients With Unresectable Barcelona Clinic Liver Cancer (BCLC) Stages C and D Advanced Hepatocellular Carcinoma Treated With 40 \u03bcm Drug-Eluting Bead Transcatheter Arterial Chemoembolization"],"prefix":"10.7759","author":[{"given":"Michael","family":"Wholey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raul","family":"Palacios III","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Wholey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Mendez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Global Cancer Observatory. Cancer today. International Agency for Research on Cancer. (2020). Accessed. March 1, 2022: http:\/\/gco.iarc.fr\/today."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel RL","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020, 70:7-30. 10.3322\/caac.21590","journal-title":"CA Cancer J Clin"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray F","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018, 68:394-424. 10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14964-1","article-title":"Hepatocellular carcinoma","volume":"362","author":"Llovet JM","year":"2003","unstructured":"Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003, 362:1907-17. 10.1016\/S0140-6736(03)14964-1","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix J","year":"2011","unstructured":"Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011, 53:1020-2. 10.1002\/hep.24199","journal-title":"Hepatology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.12.021","article-title":"EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma","volume":"48","author":"European Association for the Study of the Liver","year":"2012","unstructured":"European Association for the Study of the Liver. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012, 48:599-641. 10.1016\/j.ejca.2011.12.021","journal-title":"Eur J Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0019","article-title":"Guidelines insights: hepatobiliary cancers, version 2.2019","volume":"17","author":"Benson AB","year":"2019","unstructured":"Benson AB, D'Angelica MI, Abbott DE, et al.. Guidelines insights: hepatobiliary cancers, version 2.2019. J Natl Compr Canc Netw. 2019, 17:302-10. 10.6004\/jnccn.2019.0019","journal-title":"J Natl Compr Canc Netw"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000539","article-title":"Update on transarterial approaches to locoregional treatment in hepatocellular carcinoma","volume":"31","author":"Delhaye C","year":"2019","unstructured":"Delhaye C, Hendlisz A, Vouche M. Update on transarterial approaches to locoregional treatment in hepatocellular carcinoma. Curr Opin Oncol. 2019, 31:339-45. 10.1097\/CCO.0000000000000539","journal-title":"Curr Opin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2018.11.002","article-title":"Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence","volume":"72","author":"Raoul JL","year":"2019","unstructured":"Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat Rev. 2019, 72:28-36. 10.1016\/j.ctrv.2018.11.002","journal-title":"Cancer Treat Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-009-9711-7","article-title":"Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study","volume":"33","author":"Lammer J","year":"2010","unstructured":"Lammer J, Malagari K, Vogl T, et al.. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010, 33:41-52. 10.1007\/s00270-009-9711-7","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2011.10.019","article-title":"Radiopaque drug-eluting beads for transcatheter embolotherapy: experimental study of drug penetration and coverage in swine","volume":"23","author":"Dreher MR","year":"2012","unstructured":"Dreher MR, Sharma KV, Woods DL, et al.. Radiopaque drug-eluting beads for transcatheter embolotherapy: experimental study of drug penetration and coverage in swine. J Vasc Interv Radiol. 2012, 23:257-64.e4. 10.1016\/j.jvir.2011.10.019","journal-title":"J Vasc Interv Radiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-013-0777-x","article-title":"Chemoembolization of hepatocellular carcinoma with HepaSphere 30-60 \u03bcm. Safety and efficacy study","volume":"37","author":"Malagari K","year":"2014","unstructured":"Malagari K, Pomoni M, Moschouris H, et al.. Chemoembolization of hepatocellular carcinoma with HepaSphere 30-60 \u03bcm. Safety and efficacy study. Cardiovasc Intervent Radiol. 2014, 37:165-75. 10.1007\/s00270-013-0777-x","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.5334\/jbsr.1841","article-title":"Super-selective transarterial chemoembolization with doxorubicin-loaded drug-eluting beads sized below and above 100 microns in hepatocellular carcinoma: a comparative study","volume":"103","author":"Balli H","year":"2019","unstructured":"Balli H, Aksungur E, Khalatai B, Aikimbaev K. Super-selective transarterial chemoembolization with doxorubicin-loaded drug-eluting beads sized below and above 100 microns in hepatocellular carcinoma: a comparative study. J Belg Soc Radiol. 2019, 103:47. 10.5334\/jbsr.1841","journal-title":"J Belg Soc Radiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4329\/wjr.v9.i5.245","article-title":"Transarterial chemoembolization using 40 \u00b5m drug eluting beads for hepatocellular carcinoma","volume":"9","author":"Greco G","year":"2017","unstructured":"Greco G, Cascella T, Facciorusso A, et al.. Transarterial chemoembolization using 40 \u00b5m drug eluting beads for hepatocellular carcinoma. World J Radiol. 2017, 9:245-52. 10.4329\/wjr.v9.i5.245","journal-title":"World J Radiol"},{"key":"ref15","article-title":"Surgery and portal hypertension","volume":"1","author":"Child CG","year":"1964","unstructured":"Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg. 1964, 1:1-85.","journal-title":"Major Probl Clin Surg"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800600817","article-title":"Transection of the oesophagus for bleeding oesophageal varices","volume":"60","author":"Pugh RN","year":"1973","unstructured":"Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973, 60:646-9. 10.1002\/bjs.1800600817","journal-title":"Br J Surg"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21563","article-title":"The model for end-stage liver disease (MELD)","volume":"45","author":"Kamath PS","year":"2007","unstructured":"Kamath PS, Kim WR. The model for end-stage liver disease (MELD). Hepatology. 2007, 45:797-805. 10.1002\/hep.21563","journal-title":"Hepatology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19850815)56:4<918::aid-cncr2820560437>3.0.co;2-e","article-title":"Natural history of hepatocellular carcinoma and prognosis in relation to treatment","volume":"56","author":"Okuda K","year":"1985","unstructured":"Okuda K, Ohtsuki T, Obata H. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Cancer. 1985, 56:918-28. 10.1002\/1097-0142(19850815)56:4&lt;918::aid-cncr2820560437&gt;3.0.co;2-e","journal-title":"Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2000.16475","article-title":"Prospective validation of the Cancer of the Liver Italian Program (CLIP) score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma","volume":"32","author":"Llovet JM","year":"2000","unstructured":"Llovet JM, Bruix J. Prospective validation of the Cancer of the Liver Italian Program (CLIP) score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology. 2000, 32:679-80. 10.1053\/jhep.2000.16475","journal-title":"Hepatology"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro V","year":"1996","unstructured":"Mazzaferro V, Regalia E, Doci R, et al.. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996, 334:693-9. 10.1056\/NEJM199603143341104","journal-title":"N Engl J Med"},{"key":"ref21","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. (2017). Accessed. April 17, 2021: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf."},{"key":"ref22","article-title":"Severity Grading in Drug Induced Liver Injury","year":"2019","unstructured":"Severity Grading in Drug Induced Liver Injury. March 1, 2022 (ed). National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD); 2019."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni R","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010, 30:52-60. 10.1055\/s-0030-1247132","journal-title":"Semin Liver Dis"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.14.12844","article-title":"Survival outcomes in patients with advanced hepatocellular carcinoma treated with drug-eluting bead chemoembolization","volume":"204","author":"Ray CE Jr","year":"2015","unstructured":"Ray CE Jr, Brown AC, Green TJ, et al.. Survival outcomes in patients with advanced hepatocellular carcinoma treated with drug-eluting bead chemoembolization. AJR Am J Roentgenol. 2015, 204:440-7. 10.2214\/AJR.14.12844","journal-title":"AJR Am J Roentgenol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1477-2574.2010.00181.x","article-title":"Pretreatment assessment of hepatocellular carcinoma: expert consensus statement","volume":"12","author":"Vauthey JN","year":"2010","unstructured":"Vauthey JN, Dixon E, Abdalla EK, et al.. Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford). 2010, 12:289-99. 10.1111\/j.1477-2574.2010.00181.x","journal-title":"HPB (Oxford)"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/gut.50.6.881","article-title":"Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto","volume":"50","author":"Levy I","year":"2002","unstructured":"Levy I, Sherman M. Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut. 2002, 50:881-5. 10.1136\/gut.50.6.881","journal-title":"Gut"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet JM","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, et al.. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008, 359:378-90. 10.1056\/NEJMoa0708857","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12365","article-title":"The adverse effects of sorafenib in patients with advanced cancers","volume":"116","author":"Li Y","year":"2015","unstructured":"Li Y, Gao ZH, Qu XJ. The adverse effects of sorafenib in patients with advanced cancers. Basic Clin Pharmacol Toxicol. 2015, 116:216-21. 10.1111\/bcpt.12365","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2019.05.006","article-title":"Survival outcomes of very small drug-eluting beads used in chemoembolization of unresectable hepatocellular carcinoma","volume":"30","author":"Aal AK","year":"2019","unstructured":"Aal AK, Moawad S, Lune PV, et al.. Survival outcomes of very small drug-eluting beads used in chemoembolization of unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2019, 30:1325-34.e2. 10.1016\/j.jvir.2019.05.006","journal-title":"J Vasc Interv Radiol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2012.11.023","article-title":"Safety and efficacy of drug-eluting bead chemoembolization for hepatocellular carcinoma: comparison of small-versus medium-size particles","volume":"24","author":"Padia SA","year":"2013","unstructured":"Padia SA, Shivaram G, Bastawrous S, et al.. Safety and efficacy of drug-eluting bead chemoembolization for hepatocellular carcinoma: comparison of small-versus medium-size particles. J Vasc Interv Radiol. 2013, 24:301-6. 10.1016\/j.jvir.2012.11.023","journal-title":"J Vasc Interv Radiol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31327","article-title":"Trial design and endpoints in hepatocellular carcinoma: AASLD Consensus Conference","volume":"73 Suppl 1","author":"Llovet JM","year":"2021","unstructured":"Llovet JM, Villanueva A, Marrero JA, et al.. Trial design and endpoints in hepatocellular carcinoma: AASLD Consensus Conference. Hepatology. 2021, 73 Suppl 1:158-91. 10.1002\/hep.31327","journal-title":"Hepatology"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.10091473","article-title":"Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort","volume":"255","author":"Lewandowski RJ","year":"2010","unstructured":"Lewandowski RJ, Mulcahy MF, Kulik LM, et al.. Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology. 2010, 255:955-65. 10.1148\/radiol.10091473","journal-title":"Radiology"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-013-0654-7","article-title":"Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma","volume":"37","author":"Kalva SP","year":"2014","unstructured":"Kalva SP, Pectasides M, Liu R, et al.. Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2014, 37:381-7. 10.1007\/s00270-013-0654-7","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.5604\/16652681.1184233","article-title":"Treatment allocation in hepatocellular carcinoma: assessment of the BCLC algorithm","volume":"15","author":"Richani M","year":"2016","unstructured":"Richani M, Kolly P, Knoepfli M, et al.. Treatment allocation in hepatocellular carcinoma: assessment of the BCLC algorithm. Ann Hepatol. 2016, 15:82-90. 10.5604\/16652681.1184233","journal-title":"Ann Hepatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/91616-safety-and-long-term-survival-outcome-in-patients-with-unresectable-barcelona-clinic-liver-cancer-bclc-stages-c-and-d-advanced-hepatocellular-carcinoma-treated-with-40-m-drug-eluting-bead-transcatheter-arterial-chemoembolization","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:38:10Z","timestamp":1707507490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/91616-safety-and-long-term-survival-outcome-in-patients-with-unresectable-barcelona-clinic-liver-cancer-bclc-stages-c-and-d-advanced-hepatocellular-carcinoma-treated-with-40-m-drug-eluting-bead-transcatheter-arterial-chemoembolization"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,11]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7759\/cureus.24047","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,11]]}}}